Antisense Therapeutics Limited (ATHJF) Research

Antisense Therapeutics Limited (ATHJF) is an Australian biotechnology company dedicated to the research and development of innovative antisense pharmaceuticals. Its therapeutic pipeline includes two primary drug candidates. ATL1102, an antisense inhibitor targeting CD49d, is currently in Phase II clinical trials for a variety of inflammatory conditions, such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. The company's second candidate, ATL1103, is an advanced second-generation antisense medication. This drug works by blocking growth hormone receptor expression, which subsequently lowers levels of insulin-like growth factor-I (IGF-I) in the bloodstream, and has successfully completed Phase II clinical trials for diseases linked to excessive growth hormone activity. Antisense Therapeutics Limited was established in 2000 and operates from its base in Toorak, Australia.

Market snapshot

Symbol
ATHJF
Price
$0.01
Day change
-76.00%
Market cap
$5.6M
P/E ratio
-0.57x
52-week range
0.01-0.075
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Biofrontera AG (BFFTF)
  • TPCO Holding Corp. (GRAMF)
  • Kadimastem Ltd (KMSTF)
  • Lifeist Wellness Inc. (NXTTF)
  • Organicell Regenerative Medicine, Inc. (OCEL)
  • Simply Better Brands Corp. (PKANF)
  • RAMM Pharma Corp. (RAMMF)
  • Together Pharma Ltd (TGPHF)

Open Antisense Therapeutics Limited (ATHJF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.